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Introduction {#sec005}
============

Bladder cancer is the fifth most common cancer in Western countries and the highest cause of death among urinary malignancies in China \[[@pone.0130122.ref001]\]. RC remains the gold standard for treatment of muscle-invasive bladder cancer. This procedure is associated with significant blood loss and a common transfusion requirement. Substantial improvements in surgical techniques and perioperative management in the past two decades have markedly reduced operative and hospital mortality rates for patients with bladder carcinoma undergoing cystectomy \[[@pone.0130122.ref002], [@pone.0130122.ref003]\]. However, a large number of patients still require perioperative BTs (PBTs).

Recently, many investigators have focused on the underlying association between PBT and outcomes in various operations, such as lung cancer \[[@pone.0130122.ref004], [@pone.0130122.ref005]\], hepatocellular carcinoma \[[@pone.0130122.ref006], [@pone.0130122.ref007]\], colorectal cancer \[[@pone.0130122.ref008], [@pone.0130122.ref009]\], and prostate cancer \[[@pone.0130122.ref010]\], but their results were highly contradictory. A previous meta-analysis performed by Liu et al \[[@pone.0130122.ref011]\] demonstrated that allogeneic blood transfusion (ABT) was associated with adverse clinical outcomes for hepatocellular carcinoma patients undergoing surgery, including increased death, recurrence and complications. PBT in patients with bladder cancer was associated with increased morbidity and mortality after RC in several observational studies \[[@pone.0130122.ref012], [@pone.0130122.ref013]\], but other studies \[[@pone.0130122.ref014], [@pone.0130122.ref015]\] did not show this association in multivariable analysis. Some studies indicated that the disease characteristics (e.g., older age, higher pathological stage, longer surgical time and greater estimated blood loss) of patients who received PBT, rather than PBT itself, lead to worse outcomes \[[@pone.0130122.ref014], [@pone.0130122.ref015]\]. However, no meta-analysis has focused on the association between PBT and outcomes after RC for bladder cancer. We performed a meta-analysis of eligible studies to investigate the relationship between PBT and the clinical outcomes of RC and clarify the exact impact of PBT in patients who have undergone RC.

Methods {#sec006}
=======

2.1 Data sources {#sec007}
----------------

We conducted a systematic literature search of MEDLINE, EMBASE, the Cochrane library and BIOSIS databases for studies that were published from the time of inception to October 2014 using terms such as ''bladder and transfusion" and "cystectomy and transfusion" combined with Boolean operators where appropriate. We also searched the reference lists of relevant studies and previous meta-analyses for additional studies. Unpublished conference papers were screened from the ISI Web of Knowledge Conference Proceedings to ensure the search was as comprehensive as possible, and these data were also included when possible.

2.2 Study selection {#sec008}
-------------------

Two investigators (Y-L.W. and F-F.Y) independently extracted data from eligible studies. Disagreements were resolved by discussion and consensus. Two investigators reviewed all studies that met the inclusion and exclusion criteria. The following information was recorded for each study: (1) the study had to report the correlation between perioperative allogeneic blood transfusion and outcomes in patients undergoing RC; and (2) data were available on clinical outcomes (e.g., all-cause mortality, cancer-specific mortality, or disease recurrence). We excluded reviews, letters without original data and editorials. For duplicate publications reported by the same authors, either the higher quality or most recent publication was selected.

2.3 Data extraction and quality assessment {#sec009}
------------------------------------------

Two investigators independently reviewed each eligible article and extracted information from all of the publications that met the inclusion criteria. Disagreements were resolved by discussion among all authors. The HR with 95% CI for all-cause mortality or cancer-specific mortality was extracted. The HR was extracted from the multivariable analysis when both univariable and multivariable analyses were available. The following relevant characteristics were listed: (1) first author's name, (2) year of publication, (3) country of origin, (4) number of patients, (5) age of the patients, (6) characteristics of the study population, (7) disease stage, (8) period of follow-up, (9) period of recruitment, and (10) PBT rate ([Table 1](#pone.0130122.t001){ref-type="table"}). All relevant texts, tables and figures were reviewed for data extraction.

10.1371/journal.pone.0130122.t001

###### Characteristics of the included studies for the meta-analysis.

![](pone.0130122.t001){#pone.0130122.t001g}

  Author        Publication year   Country       Recruitment period   Follow-up, months   Study type      Number of patients   PBT rate   Age (mean, Y)   Stage pT1/pT2/≥pT3   NOS
  ------------- ------------------ ------------- -------------------- ------------------- --------------- -------------------- ---------- --------------- -------------------- -----
  **Sadeghi**   2012               USA           1989--2010           25.5                retrospective   638                  32.80%     67.6            206/98//294          6
  **Morgan**    2013               USA           2000--2008           25                  retrospective   777                  41.60%     69.5            250/196/331          6
  **Linder**    2013               USA           1980--2005           130.8               retrospective   2060                 62%        69              883/314/564          7
  **Kluth**     2014               Multination   1998--2010           36.1                retrospective   2895                 39%        67              879/681/1335         7
  **Gierth**    2014               Germany       1995--2010           70.1                retrospective   350                  63%        68              122/60/168           7
  **Abel**      2014               USA           2003--2012           18.7                retrospective   360                  67%        67.9            83/79/149            6

Abbreviations: PBT, Perioperative blood transfusion; NOS, Newcastle-Ottawa Scale

The study quality of retrospective studies was assessed independently by two reviewers with consideration of the following aspects of the Newcastle-Ottawa quality assessment scale cohort studies \[[@pone.0130122.ref016]\]. The scale focuses on three factors: Selection, Comparability and Exposure. We identified 'high' quality choices with a 'star.' A study could be awarded a maximum of one star for each numbered item within the Selection and Exposure categories. A maximum of two stars can be given for Comparability. Studies with a score equal to or higher than 6 were considered high quality.

2.4 Statistical analysis {#sec010}
------------------------

A forest plot was utilized to aggregate HRs from the multivariate analyses of individual studies in a summary HR of the effect of PBT on mortality and recurrence. Percent weights given to each study was assessed by weight analysis. Heterogeneity among the outcomes of enrolled studies in this meta-analysis was evaluated by using Chi-square based Q statistical test. And I^2^ statistic was calculated to quantify the total variation consistent with inter-study heterogeneity, ranging from 0% to 100% Heterogeneity was significant and unacceptable while I^2^ statistic was greater than 50% \[[@pone.0130122.ref017]\]. P \< 0.05 in Q statistical test was considered statistically significant. In the case of I^2^\>50%, the summary HR and the accompanying 95% CI were calculated with a random effects model, whereas we used a fixed effects model in the case of low heterogeneity as defined by I^2^≤50%. We examined publication bias with the aid of a funnel plot \[[@pone.0130122.ref018]\], and a roughly symmetrical distribution on either side of the summary estimate suggested a lack of bias. Statistical significance was defined at the level of 0.05. All statistics were performed with the Review Manager software (version 5.3.3; Cochrane collaboration, [http:ims.cochrane.org/revman/download](http://www.ims.cochrane.org/revman/download)).

We performed subgroup analyses to explore associations between characteristics (follow-up period, the number of study participants and BT ratio) of the studies and their results. Given that there are no strict standard cut-off point for each characteristic, we attempt to stratify our included studies for binary variable specifications achieved as close as possible balanced distributions. Thus, we determined the medians of follow-up period (\>30.8 or ≤30.8 month), the number of study participants (\>708 or ≤708), and BT ratio (\>51.8% or ≤51.8%) as the cut-off points. We also performed sensitivity analyses to assess the influence of individual studies on the pooled HR of all-cause mortality.

Results {#sec011}
=======

3.1 Study selection and characteristics {#sec012}
---------------------------------------

A total of 752 potentially eligible studies were screened in the preliminary search. After screening the titles and abstracts, a total of 743 articles were excluded and 9 full manuscripts were investigated in detail. Based on the inclusion and exclusion criteria, 3 of those studies were excluded \[[@pone.0130122.ref019]--[@pone.0130122.ref021]\]. Therefore, 6 studies \[[@pone.0130122.ref012]--[@pone.0130122.ref015], [@pone.0130122.ref022], [@pone.0130122.ref023]\] (7080 participants) with more detailed and sufficient evaluations met our entry criteria and were retrieved for further analysis. A flow diagram of the study selection procedure is depicted in [Fig 1](#pone.0130122.g001){ref-type="fig"}. All included studies were published, peer-reviewed papers.

![Flow diagram of study identification process.](pone.0130122.g001){#pone.0130122.g001}

All 6 eligible articles evaluated the correlation between PBT and RC outcomes. The major characteristics of the 6 studies are summarized in [Table 1](#pone.0130122.t001){ref-type="table"}. These studies were published from 2012--2014. The total number of enrolled patients was 7080, with individual samples ranging from 350--2895 (median 708). The reported mean age of the patients ranged from 67--69.5 years across the eligible studies. The follow-up period ranged from 18.7--132 months. The PBT ratio in each article ranged from 32.8% to 67%. [Table 2](#pone.0130122.t002){ref-type="table"} shows that 3 studies utilized disease recurrence, cancer-specific mortality and all-cause mortality to assess the prognostic value of PBT in patients \[[@pone.0130122.ref014], [@pone.0130122.ref021], [@pone.0130122.ref022]\]. Additionally, 1 study used cancer-specific survival and all-cause mortality \[[@pone.0130122.ref023]\], 1 study used progression-free survival and all-cause mortality \[[@pone.0130122.ref013]\], and 1 study used only all-cause mortality \[[@pone.0130122.ref015]\]. HRs and 95% CIs were directly obtained from these 6 studies. Quality assessment showed that the NOS score of each study was not less than 6, indicating that the methodological quality was generally good.

10.1371/journal.pone.0130122.t002

###### Estimation of the hazard ratio.

![](pone.0130122.t002){#pone.0130122.t002g}

  Study         Survival analysis                          Outcomes measured HR   Co-factors
  ------------- ------------------------------------------ ---------------------- ---------------------------------------------------------------------------------------------------------------------------
  **Sadeghi**   Cancer-specific mortality (multivariate)   not significant        age, chemotherapy use, pathologic stage, nodal status
                All-cause motility (multivariate)          not significant        
  **Morgan**    All-cause motility (multivariate)          not significant        age, sex, race, preoperative hematocrit, comorbidity, pathologic stage, node density, margin status, estimated blood loss
  **Linder**    Disease recurrence (multivariate)          not significant        age, sex, body mass index, preoperative hemoglobin level, estimate blood loss
                Cancer-specific mortality (multivariate)   significant            
                All-cause mortality (multivariate)         significant            
  **Kluth**     Disease recurrence (multivariate)          not significant        age, gender, pathological grade, pathologic T and N stages, positive STSM, LVI, concomitant CIS, adjuvant chemotherapy
                Cancer-specific mortality (multivariate)   not significant        
                All-cause mortality (multivariate)         not significant        
  **Gierth**    Progression-free survival (multivariate)   not significant        ASA score, age, tumor stage, information about preoperatively existing anemia, estimate blood loss
                All-cause mortality (multivariate)         significant            
  **Abel**      Disease recurrence (multivariate)          not significant        age, sex, pathologic T and N stages, body mass index, preoperative hemoglobin level, diabetes, smoking
                Cancer-specific mortality (multivariate)   not significant        
                All-cause mortality (multivariate)         not significant        

Abbreviations: STSM, Soft tissue surgical margin; LVI, Lymphovascular invasion; CIS, Carcinoma in situ; ASA, American Society of Anesthesiologists

3.2 Primary outcomes {#sec013}
--------------------

### 3.2.1 Meta-analysis of all-cause mortality, cancer-specific mortality and recurrence {#sec014}

6 studies including 7080 patients were eligible for the final analysis \[[@pone.0130122.ref012]--[@pone.0130122.ref015], [@pone.0130122.ref022], [@pone.0130122.ref023]\]. A combined analysis of the relationship between PBT and all-cause mortality of patients undergoing RC is shown in forest plots ([Fig 2](#pone.0130122.g002){ref-type="fig"}). Our analysis suggested that PBT was associated with all-cause mortality after RC (HR: 1.19; 95% CI: 1.11--1.27; p\<0.00001), with moderate heterogeneity between studies (I^2^ = 48%). Four studies (n = 5953) provided data on the association of PBT and cancer-specific mortality. We pooled the trial results in a meta-analysis and found a significant association between PBT and cancer-specific mortality, with an HR of 1.17 (95% CI: 1.06--1.30, P = 0.002; I^2^ = 0%, P = 0.48). Three studies (n = 5315) that evaluated cancer recurrence presented a significant difference in patients who received PBT (HR: 1.14; 95% CI: 1.03--1.27; I^2^ = 0%, P = 0.8) ([Fig 2](#pone.0130122.g002){ref-type="fig"}).

![Fixed-effect model forest plots of HRs.\
(A) All-cause mortality, (B) Cancer-specific mortality, (C) Cancer recurrence. SE: standard error; CI: confidence interval; IV: inverse variance.](pone.0130122.g002){#pone.0130122.g002}

### 3.2.2 Subgroup analysis of all-cause mortality {#sec015}

Subgroup analysis by the period of follow-up suggested that studies with a follow-up \>30.8 months and ≤30.8 months had a significant impact on overall survival (\>30.8: HR: 1.20, 95% CI: 1.11--1.30, I^2^ = 76%, P = 0.01; ≤30.8: HR: 1.13, 95% CI: 0.97--1.33, I^2^ = 0%, P = 0.73). When grouped according to the number of patients, studies with participants \>708 and ≤708 suggested significant results (\>708: HR: 1.16, 95% CI: 1.07--1.26, I^2^ = 56%, P = 0.0002; ≤708: HR: 1.29, 95% CI: 1.10--1.52, I^2^ = 47%, P = 0.15). We then focused on the median BT ratio in each study. The study with a \>51.8% showed a significant impact on overall survival (HR: 1.34, 95% CI: 1.19--1.50, I^2^ = 21%, P = 0.28), but the study with a ≤51.8% BT ratio showed a slight impact on all-cause mortality (HR: 1.10, 95% CI = 1.00--1.21, I^2^ = 0%, P = 0.85) ([Table 3](#pone.0130122.t003){ref-type="table"}).

10.1371/journal.pone.0130122.t003

###### Subgroup analyses for all-cause mortality.
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                                                                 No. of studies   No. of cases   Pooled HR (95% CI)   P value     Within-stratum heterogeneity
  -------------------------------------------------------------- ---------------- -------------- -------------------- ----------- ------------------------------
  **Follow-up (months)** [\*](#t003fn002){ref-type="table-fn"}                                                                    
  **\>30.8**                                                     3                5305           1.20 (1.11--1.30)    \<0.00001   I2 = 76%, p = 0.01
  **≤30.8**                                                      3                1775           1.13 (0.97--1.33)    0.12        I2 = 0%, p = 0.73
  **No. of patients** [\*\*](#t003fn003){ref-type="table-fn"}                                                                     
  **\>708**                                                      3                5732           1.16 (1.07--1.26)    0.0002      I2 = 56%, p = 0.11
  **≤708**                                                       3                1348           1.29 (1.10--1.52)    0.002       I2 = 47%, p = 0.15
  **PBT ratio** [\*\*\*](#t003fn004){ref-type="table-fn"}                                                                         
  **\>51.8%**                                                    3                2770           1.34 (1.19--1.50)    \<0.00001   I2 = 21%, p = 0.28
  **≤51.8%**                                                     3                4310           1.10 (1.00--1.21)    0.04        I2 = 0%, p = 0.85

HR: Hazard ratio; CI: Confidence interval

\* Median follow-up period of included studies: 30.8 months

\*\*Median patients' number of included studies: 708

\*\*\*Median PBT ratio of included studies: 51.8%

3.3 Sensitivity analysis and publication bias {#sec016}
---------------------------------------------

A sensitivity analysis was conducted, in which one study was deleted at a time, to gauge the stability of our results. The corresponding pooled HR for all-cause mortality did not significantly change (HR was between 1.17 and 1.26), which suggests that the result was robust.

Publication bias was tested in this meta-analysis using funnel plots. [Fig 3](#pone.0130122.g003){ref-type="fig"} shows that the funnel plots presented no proof of obvious publication bias in any of the included studies for all-cause mortality or cancer-specific mortality or recurrence, which suggests no publication bias.

![Funnel plots for publication bias in studies of PBT in patients with bladder cancer who underwent RC.\
(A) All-cause mortality. (B) Cancer-specific mortality. (C) Cancer recurrence.](pone.0130122.g003){#pone.0130122.g003}

Discussion {#sec017}
==========

To the best of our knowledge, this is the first meta-analysis that has been conducted on the impact of PBT on mortality and recurrence in patients with bladder cancer who underwent RC. The present meta-analysis combined the outcomes available in 6 published studies and concluded that PBT was associated with significantly increased risks of all-cause mortality (HR: 1.19, 95% CI: 1.11--1.27, P\<0.00001) and worse cancer-specific mortality (HR: 1.17, 95% CI: 1.06--1.30, P = 0.002) and recurrence (HR: 1.14, 95% CI: 1.03--1.27, P = 0.01). Additionally, the sensitivity analysis showed that the significant association between PBT and increased mortality and cancer recurrence remained regardless of whether one of the included studies was omitted, which suggests the robustness of this result. A quality assessment was performed independently and reproducibly by two authors according to Newcastle-Ottawa guidelines. We ensured that the included studies were high quality by comprehensively and scientifically evaluating the articles.

Numerous reasons may explain why PBT was associated with an increased risk of death and recurrence in patients who underwent surgical resection of cancer. One hypothesis underlying this association is the possible immunosuppressive effect of PBT \[[@pone.0130122.ref024], [@pone.0130122.ref025]\]. The infusion of foreign antigens in transfused blood products induces immune suppression, anergy and clonal deletion in studies in experimental animals \[[@pone.0130122.ref026]\], which may predispose already immunosuppressed cancer patients to tumor cell spread and facilitate tumor growth and reduced survival. However, most studies that have evaluated proposed mechanisms have been performed in rodents, and these findings may not be applicable to the human immune system \[[@pone.0130122.ref027]\]. Other possible mechanisms that have been postulated to explain the noted association between PBT and survival include the increased incidence of postoperative infection and blood type incompatibility \[[@pone.0130122.ref028]\].

The baseline characteristics of patients might have affected the conclusions of each included report. Therefore, further subgroup analyses were stratified using patient number, follow-up duration and PBT ratio. A significant association was observed between PBT and increased mortality when the follow-up period was more than 39 months. This finding should be interpreted cautiously as a worse long-term survival of PBT, which was shown in several studies \[[@pone.0130122.ref029]--[@pone.0130122.ref031]\], but not in RC of bladder cancer. Another explanation may be due to increased mortality with prolonged follow-up times. PBT ratios ranged from 32.8%-67% in the 6 included studies. The subgroup analysis by BT ratio revealed that the increased all-cause mortality occurred when the BT ratio was high. These differences in transfusion ratios may be explained by several reasons, including different patient populations and differences in traditions and norms. If the significant institutional-level differences of the patients are ignored, we believe that the higher rate of BT (62.8% in the ≥51.8% subgroup and 43.3% in the \<51.8% subgroup) may cause by unnecessary blood transfusion, which may increase the all-cause mortality of patients who underwent RC (HR: 1.34, 1.19--1.50, P\<0.05, vs. HR: 1.10, 1.00--1.21, P\<0.05, respectively). Perioperative blood loss is an important operative complication in patients undergoing major surgery, which may increase the chance of PBT, subsequent postoperative morbidity and mortality \[[@pone.0130122.ref032]\]. Therefore, individual centers should pay attention to their current transfusion practice and reduce intraoperative blood loss as much as possible.

The timing of blood transfusion is also an important factor for clinical outcomes. Gierth et al. showed that intraoperative and postoperative blood transfusions independently influence progression-free survival and overall survival \[[@pone.0130122.ref013]\]. Abel et al. combined outcomes from two independent cohorts of consecutive patients with bladder cancer treated with RC and demonstrated that intraoperative BT (HR: 1.41, 95% CI: 1.22--1.63, P\<0.00001), but not postoperative BT (HR: 1.04, 95% CI: 0.87--1.24, P = 0.65), was associated with an increased risk of bladder cancer all-cause mortality \[[@pone.0130122.ref022]\].

The present meta-analysis has limitations. First, the most important limitation is that all of the included studies were retrospective samples rather than randomized controlled trials, and the clinicians could not be blinded to the selection of patients who received BT. Multivariable models were used in the included studies, but the adjusted cofounders were not the same for the adjusted HRs ([Table 3](#pone.0130122.t003){ref-type="table"}). Therefore, we were unable to conduct stratified analyses based on possible confounders, such as preoperative hemoglobin levels or perioperative blood losses. Some studies demonstrated that estimated blood loss was an independent factor to predict survival or recurrence after surgery \[[@pone.0130122.ref033], [@pone.0130122.ref034]\], but only 3 of the 6 studies in this meta-analysis considered intraoperative blood loss \[[@pone.0130122.ref013], [@pone.0130122.ref015], [@pone.0130122.ref021]\]. Several reports suggested that intraoperative blood loss during surgery for cancer is a critical risk factor of mortality and recurrence. Notably, Linder et al. repeated their multivariate analysis to include the variable of estimate blood loss in response to this issue, and they discovered that PBT remained significantly associated with increased risks of cancer-specific mortality (HR: 1.26; P = 0.017) and all-cause mortality (HR: 1.30; P = 0.0002) \[[@pone.0130122.ref021]\]. Second, studies performed with positive results or significant outcomes are more apt to be published, which suggests a potential publication bias. The sample sizes of enrolled research (from 350 to 2,895) varied widely; therefore, the statistical power or weight of each study was greatly different, which inevitably causes bias to varying degrees. In addition, one report did not provide sufficient data and was excluded from our analysis \[[@pone.0130122.ref019]\]. Third, reports in languages other than English were excluded, so a potential language bias may be present in our meta-analysis.

The results of our meta-analysis confirmed that PBT might be an independent predicative factor of mortality and disease recurrence in bladder cancer patients who undergo RC. Autotransfusion is safer than ABT \[[@pone.0130122.ref035]\], but the amount of phlebotomized blood is insufficient to completely replace blood loss. Substantial variation exists in the hospital-level use of PBT for patients undergoing RC, which might be related to different rates of cancer recurrence and all-cause mortality for these patients. Clinicians should reconsider the use of blood conservation methods to avoid transfusions, especially in patents who require limited amounts of transfused blood products. Further studies are needed to investigate a standard to determine whether a patient requires a BT. Regardless, every effort should be made to reduce intraoperative blood loss that requires BT because it may be associated with a decrease in long-term survival. The conclusions of this study should be interpreted with caution based on the study limitations. Future large studies with rigorously designed methodologies are warranted to confirm our results.
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